Olsalazine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Olsalazine
- Pharmacist Assessment Report
- Olsalazine: From Inflammatory Bowel Disease Therapy to Myelodysplastic Syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Olsalazine: From Inflammatory Bowel Disease Therapy to Myelodysplastic Syndrome
One-Sentence Summary
Olsalazine is a dimer of 5-aminosalicylic acid (5-ASA), an anti-inflammatory agent that acts locally in the colon. The TxGNN model predicts it may be effective for myelodysplastic syndrome, but no clinical trials and no publications currently support this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Canadian licence data |
| Predicted New Indication | Myelodysplastic syndrome |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, olsalazine is a 5-ASA dimer that colonic bacteria cleave into two active molecules. Its anti-inflammatory effects (local COX and lipoxygenase inhibition, NF-kB and PPAR-gamma modulation) act mainly on the gut lining, and very little of the drug is absorbed into the bloodstream.
The review found no plausible mechanistic link between this action and myelodysplastic syndrome, a clonal bone marrow disorder. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The other top predictions point the same way:
- Bone marrow and blood disorders: unclassified myelodysplastic syndrome, refractory cytopenia of childhood, aregenerative anemia, severe congenital hypochromic anemia with ringed sideroblasts, and partial deletion of the long arm of chromosome 5. The del(5q) abnormality is a cytogenetic finding rather than a treatable disease, and it likely reflects the same cluster of predictions as myelodysplastic syndrome.
- Hair disorders: hypotrichosis simplex of the scalp, congenital hypotrichosis milia, alopecia, and diffuse alopecia areata. Alopecia areata is T-cell-mediated autoimmunity, which olsalazine’s local mucosal action does not target.
For aregenerative anemia, the relationship may point toward harm instead of benefit. Drugs in the 5-ASA class have rare reports of blood disorders, including aplastic anemia, as adverse effects.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02063808 | DIPENTUM | Not stated | Not stated |
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for these.
Drug Interactions: The interaction screening returned 100 potential interactions. The first 20 are summarised below.
- Major:
- Human immunoglobulin G (intravenous)
- Human botulinum neurotoxin A/B immune globulin
- Cidofovir
- Iothalamic acid
- Moderate:
- NSAIDs: ketorolac, ibuprofen, celecoxib, diclofenac
- Antimicrobials and antivirals: acyclovir, amikacin, bacitracin, capreomycin, colistimethate
- Amphotericin B (including the lipid complex)
- Azathioprine
- Ibandronate
- Chlorpropamide
- Cisplatin
- Clofarabine
Many of these are nephrotoxic agents, so kidney function would need attention if any are combined with olsalazine.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the TxGNN model (deep learning), whose score may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials or publications, and no mechanistic link exists between a locally acting gut anti-inflammatory drug with minimal systemic absorption and a bone marrow disorder. The safety data also has gaps.
To proceed, the following is needed:
- Mechanism of action data for olsalazine
- Package insert warnings and contraindications from Health Canada
- Preclinical or mechanistic evidence linking 5-ASA to haematopoietic or myelodysplastic biology
- A literature and trial search specific to olsalazine or 5-ASA in myelodysplastic syndrome
- A review of the haematological safety signals associated with 5-ASA-class drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.